Teva (NYSE: TEVA) reported third-quarter results today that matched analysts’ consensus forecast. The company will maintain its guidance for the rest of the year. Teva, which has dual headquarters in Israel and Parsippany, N.J., reported a loss of -$4.3 billion or -$3.97 per share on revenue of $3.9 billion for the quarter ended September 30, […]
Teva
Teva wins EU nod for Ajovy migraine prophylactic
Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization in the European Union for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month. The Israel-based company said that Ajovy is a humanized monoclonal antibody that binds to the calcitonin gene-related […]
Ocular continues personnel shakeup with new CMO | Personnel Moves – Sept. 13, 2017
After Ocular Therapeutix‘s (NSDQ:OCUL) founder & CEO, Amar Swahney, stepped down earlier this year, pharma executive Antony Mattessich stepped in to assume the corner office. He signaled some major changes to the company’s business strategy in a call with analysts last month, including an attempt to ‘aggressively seek new partnerships’ and ‘enhance [the company’s] credibility’. As […]
